Business Context and Reporting Period
Company: Aprea Therapeutics, Inc. (APRE)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2024
Business Overview: Aprea is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. Following the acquisition of Atrin Pharmaceuticals in 2022, the company shifted its focus from p53 reactivators to DNA damage response (DDR) inhibitors. The pipeline consists of two clinical-stage assets: APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor), plus an undisclosed preclinical DDR inhibitor.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Grant Revenue | $1.5 million | $0.6 million |
| Total Operating Expenses | $15.8 million | $16.1 million |
| Net Loss | $(13.0) million | $(14.3) million |
| Cash and Cash Equivalents (Dec 31, 2024) | $22.8 million | $21.6 million |
| Accumulated Deficit (Dec 31, 2024) | $(321.0) million | $(308.1) million |
| Net Cash Used in Operating Activities | $(13.6) million | $(12.2) million |
| Net Cash Provided by Financing Activities | $14.8 million | $5.1 million |
Note: The company has no commercial product revenue. Revenue is derived solely from government grants (primarily NIH).
Material Changes vs. Prior Period
- Revenue Growth: Grant revenue increased by approximately $0.9 million (158%) year-over-year, driven by increased funding from the National Cancer Institute.
- Expense Management: Total operating expenses decreased slightly by $0.2 million. General and Administrative (G&A) expenses dropped by $2.0 million, primarily due to reduced severance costs compared to 2023. This was offset by a $1.7 million increase in Research and Development (R&D) expenses.
- R&D Allocation: R&D spending increased to support the initiation of the ACESOT-1051 Phase 1 trial for APR-1051 and the expansion of the ABOYA-119 Phase 1/2a trial for ATRN-119.
- Capital Raise: In March 2024, the company completed a private placement raising approximately $16.0 million in gross proceeds (net of fees ~$14.7 million) through the sale of common stock and warrants.
Guidance, Outlook, and Risks
Going Concern Warning
Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least 12 months from the filing date. While cash on hand ($22.8 million) is projected to fund operations into the first quarter of 2026, the company requires additional financing to sustain operations beyond that period.
Clinical Outlook
- APR-1051 (WEE1 Inhibitor): Phase 1 dose-escalation (ACESOT-1051) is ongoing. Cohort 5 (70 mg) was enrolling as of March 4, 2025. Preliminary data indicates the drug is safe and well-tolerated with no hematologic toxicity. Dose-escalation completion is expected in H1 2026.
- ATRN-119 (ATR Inhibitor): Phase 1/2a (ABOYA-119) is ongoing. Seven dose cohorts have been completed or are enrolling. The protocol was amended to include twice-daily dosing to potentially enhance efficacy. Phase 1 readout is expected in H2 2025, with Recommended Phase 2 Dose (RP2D) determination in Q1 2026.
Key Risks
- Liquidity: Dependence on future equity or debt financing, which may not be available on acceptable terms.
- Clinical Failure: Early-stage clinical trials may not demonstrate safety or efficacy required for regulatory approval.
- Third-Party Reliance: Dependence on contract manufacturers for API and drug product supply.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2026" cash runway projection given the high burn rate of clinical trials.
- Financing Terms: Review the terms of the March 2024 private placement warrants (Tranche A and B) and their potential dilution impact upon exercise.
- Clinical Milestones: Monitor the safety data readouts for APR-1051 and ATRN-119 expected in late 2025 to validate the "safe and well-tolerated" preliminary claims.
- Grant Dependency: Assess the sustainability of NIH grant revenue as a funding source versus the need for commercial capital.